Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura

World News: . []

HAYWARD Calif March 12 2018 GLOBE NEWSWIRE -- Anthera Pharmaceuticals Inc NasdaqANTH announced today that Sollpura did not meet the non-inferiority margin of the CFA primary endpoint in the RESULT Phase 3 clinical study of exocrine panc reatic ...

More news and information about Anthera Pharmaceuticals, Inc.

Published By:

Globe Newswire: 12:00 GMT Monday 12th March 2018

Published: .

Search for other references to "anthera" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us